Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market

Erectile and Sexual Functions and Dysfunctions

Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States

J Sex Med

Nunes AP, Seeger JD, Stewart A, Gupta A, McGraw T

doi: 10.1016/j.jsxm.2021.06.010

The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review

Urology.

Tan P, Liu L, Wei S, Tang Z, Yang L, Wei Q

doi: 10.1016/

Reproductive Health

Impact of estrogen type on cardiovascular safety of combined oral contraceptives

Contraception.

Dinger J, Do Minh T, Heinemann K

doi: 10.1016/

Benign Prostatic Hyperplasia (BPH)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis

PLoS One.

Kim JH, Baek MJ, Sun HY, Lee B, Li S, Khandwala Y, Del Giudice F, Chung BI

doi: 10.1371/journal.pone.

Hypogonadism

Clinical and biochemical correlates of male hypogonadism in type 2 diabetes

Andrology.

Herrero A, Marcos M, Galindo P, Miralles JM, Corrales JJ

doi: 10.1111/andr.12433.

Further Publications Urology

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

Diabetes Obes Metab

Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Amod A, Marre M, Joseph A, Lage A, Scott C, Bakris GL, FIDELIO-DKD Investigators.

doi: 10.1111/dom.14558

Erectile and Sexual Functions and Dysfunctions

Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil

Int J Impot Res.

Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, Romero J

doi: 10.1038/s41443-018-0046-2.

Uro-Oncology

Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth

Prostate.

Carbonetti G, Converso C, Clement T, Wang C, Trotman L, Ojima I, Kaczocha M

doi: 10.1002/pros.23921.

Pregnancy and Childbirth

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months

Obstet Gynecol.

Turok DK, Nelson AL, Dart C, Schreiber CA, Peters K, Schreifels MJ, Katz B

doi: 10.1097/AOG.0000000000003756.

Related content